Sign in or create an account to add this stock to your watchlist.
About Eagle Pharmaceuticals (NASDAQ:EGRX)
Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL). Its product candidates includes include EP-3101, (bendamustine ready-to-dilute) for CLL and indolent B-cell NHL; EP-4104, a dantrolene sodium for exertional heat stroke; EGL-4104-C-1702, dantrolene sodium for drug induced hyperthermia; EP-5101 (pemetrexed) for lung cancer and mesothelioma; and EGL-5385-C-1701 (fulvestrant) for breast cancer. Eagle Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EGRX
CUSIPN/A
Phone201-326-5300
Debt
Debt-to-Equity Ratio0.23
Current Ratio5.87
Quick Ratio5.66
Price-To-Earnings
Trailing P/E Ratio19.70
Forward P/E Ratio34.31
P/E GrowthN/A
Sales & Book Value
Annual Sales$236.71 million
Price / Sales4.13
Cash Flow$3.9449 per share
Price / Cash16.70
Book Value$12.01 per share
Price / Book5.49
Profitability
EPS (Most Recent Fiscal Year)$3.37
Net Income$51.94 million
Net Margins15.32%
Return on Equity21.89%
Return on Assets15.09%
Miscellaneous
Employees108
Outstanding Shares14,840,000
Eagle Pharmaceuticals (NASDAQ:EGRX) Frequently Asked Questions
What is Eagle Pharmaceuticals' stock symbol?
Eagle Pharmaceuticals trades on the NASDAQ under the ticker symbol "EGRX."
How will Eagle Pharmaceuticals' stock buyback program work?
Eagle Pharmaceuticals declared that its Board of Directors has initiated a share repurchase program on Thursday, August 10th 2017, which permits the company to repurchase $100,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to reacquire up to 13.3% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company's leadership believes its shares are undervalued.
How were Eagle Pharmaceuticals' earnings last quarter?
Eagle Pharmaceuticals (NASDAQ:EGRX) announced its quarterly earnings data on Thursday, May, 10th. The specialty pharmaceutical company reported $0.53 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.68 by $0.15. The specialty pharmaceutical company earned $46.60 million during the quarter, compared to analyst estimates of $48.88 million. Eagle Pharmaceuticals had a return on equity of 21.89% and a net margin of 15.32%. The firm's revenue was down 39.3% on a year-over-year basis. During the same period in the prior year, the firm earned $1.42 EPS. View Eagle Pharmaceuticals' Earnings History.
What price target have analysts set for EGRX?
3 brokerages have issued 12-month price targets for Eagle Pharmaceuticals' shares. Their predictions range from $54.00 to $79.00. On average, they expect Eagle Pharmaceuticals' stock price to reach $68.00 in the next year. View Analyst Ratings for Eagle Pharmaceuticals.
What are Wall Street analysts saying about Eagle Pharmaceuticals stock?
Here are some recent quotes from research analysts about Eagle Pharmaceuticals stock:
- 1. Mizuho analysts commented, "We don’t yet have this product in our model, and don’t expect it to be a meaningful revenue generator because Treanda powder currently has minimal market share. Big bag" may provide insurance if Eagle fails to bar Treanda generics from the market via its Orphan Drug litigation, in our view. The Fulvestrant clinical trial is fully enrolled, and data are expected in the fall. Additionally, the FDA accepted Eagle’s Vasostrict ANDA, which Endo indicated would be subject to the full litigation pathway. We have no estimates for the Ryanodex program for nerve agent exposure and note that Eagle did not provide an update on its drug- induced hyperthermia program, which we believe could get dropped. We summarize 1Q:18 performance below and reiterate our Underperform rating." (5/10/2018)
- 2. According to Zacks Investment Research, "Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey. " (3/1/2018)
Who are some of Eagle Pharmaceuticals' key competitors?
Some companies that are related to Eagle Pharmaceuticals include Blueprint Medicines (BPMC), Array Biopharma (ARRY), Ultragenyx Pharmaceutical (RARE), Amicus Therapeutics (FOLD), Supernus Pharmaceuticals (SUPN), Ascendis Pharma (ASND), Portola Pharmaceuticals (PTLA), Ironwood Pharmaceuticals (IRWD), Clovis Oncology (CLVS), Tesaro (TSRO), Emergent BioSolutions (EBS), Horizon Pharma (HZNP), Global Blood Therapeutics (GBT), The Medicines (MDCO) and Arena Pharmaceuticals (ARNA).
Who are Eagle Pharmaceuticals' key executives?
Eagle Pharmaceuticals' management team includes the folowing people:
- Mr. Scott L. Tarriff, Chief Exec. Officer and Director (Age 58)
- Mr. David M. Pernock, Pres and Chief Commercial Officer (Age 65)
- Dr. Adrian Hepner M.D., Ph.D., Chief Medical Officer and Exec. VP (Age 57)
- Mr. Pete A. Meyers, Chief Financial Officer and Principal Accounting Officer (Age 48)
- Mr. Daniel O'Connor, Exec. VP of Biologics and Corp. Devel. (Age 38)
Has Eagle Pharmaceuticals been receiving favorable news coverage?
News articles about EGRX stock have been trending somewhat positive this week, Accern reports. The research firm ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Eagle Pharmaceuticals earned a media sentiment score of 0.06 on Accern's scale. They also gave media headlines about the specialty pharmaceutical company an impact score of 46.30 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
Who are Eagle Pharmaceuticals' major shareholders?
Eagle Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.42%), Park West Asset Management LLC (7.08%), Victory Capital Management Inc. (6.87%), Iridian Asset Management LLC CT (5.89%), LSV Asset Management (5.79%) and First Eagle Investment Management LLC (3.38%). Company insiders that own Eagle Pharmaceuticals stock include David Pernock, Douglas L Braunstein, Pete A Meyers, Proquest Investments Iv, LP, Richard A Edlin, Sander A Flaum, Sander A Flaum, Steven B Ratoff and Steven L Krill. View Institutional Ownership Trends for Eagle Pharmaceuticals.
Which major investors are selling Eagle Pharmaceuticals stock?
EGRX stock was sold by a variety of institutional investors in the last quarter, including Prudential Financial Inc., First Eagle Investment Management LLC, Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp, Old Mutual Global Investors UK Ltd., GSA Capital Partners LLP, Victory Capital Management Inc., Royal Bank of Canada and Iridian Asset Management LLC CT. View Insider Buying and Selling for Eagle Pharmaceuticals.
Which major investors are buying Eagle Pharmaceuticals stock?
EGRX stock was bought by a variety of institutional investors in the last quarter, including LSV Asset Management, Guggenheim Capital LLC, UBS Group AG, Schwab Charles Investment Management Inc., BlackRock Inc., Park West Asset Management LLC, Virginia Retirement Systems ET AL and Federated Investors Inc. PA. Company insiders that have bought Eagle Pharmaceuticals stock in the last two years include David Pernock, Douglas L Braunstein, Pete A Meyers and Richard A Edlin. View Insider Buying and Selling for Eagle Pharmaceuticals.
How do I buy shares of Eagle Pharmaceuticals?
Shares of EGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Eagle Pharmaceuticals' stock price today?
One share of EGRX stock can currently be purchased for approximately $66.30.
How big of a company is Eagle Pharmaceuticals?
Eagle Pharmaceuticals has a market capitalization of $956.29 million and generates $236.71 million in revenue each year. The specialty pharmaceutical company earns $51.94 million in net income (profit) each year or $3.37 on an earnings per share basis. Eagle Pharmaceuticals employs 108 workers across the globe.
How can I contact Eagle Pharmaceuticals?
Eagle Pharmaceuticals' mailing address is 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677. The specialty pharmaceutical company can be reached via phone at 201-326-5300 or via email at [email protected]
MarketBeat Community Rating for Eagle Pharmaceuticals (EGRX)
MarketBeat's community ratings are surveys of what our community members think about Eagle Pharmaceuticals and other stocks. Vote "Outperform" if you believe EGRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EGRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Eagle Pharmaceuticals (NASDAQ:EGRX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for Eagle Pharmaceuticals in the last 12 months. Their average twelve-month price target is $68.00, suggesting that the stock has a possible upside of 3.22%. The high price target for EGRX is $79.00 and the low price target for EGRX is $54.00. There are currently 1 sell rating and 2 buy ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Hold |
| Consensus Rating Score: | 2.33 | 2.33 | 2.33 | 2.33 |
| Ratings Breakdown: | 1 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $68.00 | $63.3333 | $63.6667 | $62.3333 |
| Price Target Upside: | 3.22% upside | 20.91% upside | 7.87% upside | 12.68% upside |
Eagle Pharmaceuticals (NASDAQ:EGRX) Consensus Price Target History
Eagle Pharmaceuticals (NASDAQ:EGRX) Analyst Ratings History
Show:
(Data available from 5/23/2016 forward)
Eagle Pharmaceuticals (NASDAQ:EGRX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Eagle Pharmaceuticals (NASDAQ EGRX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 19.50%
Eagle Pharmaceuticals (NASDAQ EGRX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/6/2018 | Sander A Flaum | Director | Sell | 2,340 | $53.94 | $126,219.60 | |  |
| 8/16/2017 | Pete A Meyers | CFO | Buy | 350 | $55.45 | $19,407.50 | 700 | |
| 8/9/2017 | Douglas L Braunstein | Director | Buy | 20,400 | $49.07 | $1,001,028.00 | | |
| 6/12/2017 | Pete A Meyers | CFO | Buy | 350 | $71.49 | $25,021.50 | 350 | |
| 5/19/2017 | David Pernock | Insider | Buy | 255 | $79.69 | $20,320.95 | 966 | |
| 5/16/2017 | David Pernock | Insider | Buy | 200 | $82.24 | $16,448.00 | 711 | |
| 4/25/2017 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 54,180 | $88.38 | $4,788,428.40 | | |
| 4/3/2017 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 91,332 | $83.09 | $7,588,775.88 | | |
| 3/29/2017 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 106,468 | $83.01 | $8,837,908.68 | | |
| 3/28/2017 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 6,182 | $83.02 | $513,229.64 | | |
| 3/27/2017 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 39,431 | $83.00 | $3,272,773.00 | | |
| 3/23/2017 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 1,200 | $83.05 | $99,660.00 | | |
| 3/23/2017 | Steven L Krill | EVP | Sell | 14,125 | $81.07 | $1,145,113.75 | 5,023 | |
| 3/22/2017 | Richard A Edlin | Director | Buy | 6,000 | $79.44 | $476,640.00 | 29,400 | |
| 3/21/2017 | David Pernock | Insider | Buy | 61 | $83.98 | $5,122.78 | 511 | |
| 3/20/2017 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 100,000 | $82.06 | $8,206,000.00 | | |
| 3/9/2017 | David Pernock | Insider | Buy | 450 | $77.84 | $35,028.00 | 450 | |
| 1/4/2017 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 65,114 | $85.16 | $5,545,108.24 | | |
| 12/13/2016 | Steven B Ratoff | Director | Sell | 10,000 | $75.01 | $750,100.00 | 23,324 | |
| 11/28/2016 | Sander A Flaum | Director | Sell | 5,000 | $78.66 | $393,300.00 | 11,374 | |
| 11/11/2016 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 34,486 | $85.15 | $2,936,482.90 | | |
| 11/9/2016 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 153,830 | $79.29 | $12,197,180.70 | | |
| 11/7/2016 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 5,030 | $75.39 | $379,211.70 | | |
| 11/4/2016 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 245,770 | $71.02 | $17,454,585.40 | | |
| 9/30/2016 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 22,100 | $70.06 | $1,548,326.00 | | |
| 9/29/2016 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 77,900 | $70.04 | $5,456,116.00 | | |
| 9/21/2016 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 99,795 | $66.17 | $6,603,435.15 | | |
| 9/8/2016 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 70,925 | $62.50 | $4,432,812.50 | | |
| 8/24/2016 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 28,870 | $63.00 | $1,818,810.00 | | |
| 8/17/2016 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 99,795 | $61.36 | $6,123,421.20 | | |
| 8/16/2016 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 60,150 | $61.67 | $3,709,450.50 | | |
| 8/15/2016 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 24,949 | $60.77 | $1,516,150.73 | | |
| 5/13/2016 | Proquest Management Llc | Major Shareholder | Sell | 17,980 | $40.72 | $732,145.60 | | |
| 4/1/2016 | Scott Tarriff | CEO | Sell | 30,765 | $40.63 | $1,249,981.95 | 1,369,946 | |
| 3/15/2016 | Michael Graves | Director | Buy | 1,000 | $56.73 | $56,730.00 | 1,000 | |
| 2/1/2016 | Scott Tarriff | CEO | Sell | 18,360 | $68.08 | $1,249,948.80 | 1,420,491 | |
| 12/22/2015 | Sander A. Flaum | Director | Sell | 13,025 | $54.81 | $713,900.25 | 16,374 | |
| 12/1/2015 | Scott Tarriff | CEO | Sell | 14,050 | $88.93 | $1,249,466.50 | 1,453,400 | |
| 11/2/2015 | Scott Tarriff | CEO | Sell | 19,339 | $64.63 | $1,249,879.57 | 1,467,450 | |
| 10/1/2015 | Scott Tarriff | CEO | Sell | 17,878 | $69.92 | $1,250,029.76 | 1,486,789 | |
| 9/1/2015 | Scott Tarriff | CEO | Sell | 16,245 | $76.95 | $1,250,052.75 | 1,504,667 | |
| 7/1/2015 | Scott Tarriff | CEO | Sell | 135,710 | $46.34 | $6,288,801.40 | | |
| 6/16/2015 | Steven L Krill | Insider | Sell | 9,980 | $81.60 | $814,368.00 | | |
| 2/18/2014 | Jay Moorin | Director | Buy | 333,333 | $15.00 | $4,999,995.00 | | |
(Data available from 1/1/2013 forward)
Eagle Pharmaceuticals (NASDAQ EGRX) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Eagle Pharmaceuticals (EGRX) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - May 21 at 9:26 AM |
| Eagle Pharmaceuticals (EGRX) Rating Increased to Strong-Buy at BidaskClub
www.americanbankingnews.com - May 19 at 1:01 PM |
 | Form 8-K EAGLE PHARMACEUTICALS, For: May 16
www.streetinsider.com - May 18 at 9:38 AM |
 | Eagle Pharmaceuticals, Inc. Granted Final FDA Approval for Bendamustine Hydrochloride Ready-to-Dilute Solution in ...
www.businesswire.com - May 18 at 9:38 AM |
 | BRIEF-Eagle Pharmaceuticals Gets Final FDA Approval For Bendamustine Hydrochloride Ready-To-Dilute Solution In ...
www.reuters.com - May 18 at 9:38 AM |
| $51.50 Million in Sales Expected for Eagle Pharmaceuticals (EGRX) This Quarter
www.americanbankingnews.com - May 18 at 1:42 AM |
| Eagle Pharmaceuticals' (EGRX) Underperform Rating Reaffirmed at Mizuho
www.americanbankingnews.com - May 17 at 3:27 PM |
 | Market Trends Toward New Normal in Agios Pharmaceuticals, Corcept Therapeutics ...
globenewswire.com - May 17 at 9:13 AM |
| Eagle Pharmaceuticals (EGRX) Expected to Announce Earnings of $0.96 Per Share
www.americanbankingnews.com - May 16 at 11:12 PM |
| Eagle Pharmaceuticals (EGRX) Says it was Granted Final FDA Approval for Bendamustine Hydrochloride Ready-to-Dilute Solution in 500ml Admixture
www.streetinsider.com - May 16 at 4:54 PM |
 | Eagle Pharmaceuticals, Inc. Granted Final FDA Approval for Bendamustine Hydrochloride Ready-to-Dilute Solution in a 500ml Admixture
finance.yahoo.com - May 16 at 9:14 AM |
 | FDA approves Eagle Pharmaceuticals' RTD HCI solution in a 500ml admixture
seekingalpha.com - May 16 at 7:52 AM |
| Eagle Pharmaceuticals (EGRX) Upgraded to Hold at ValuEngine
www.americanbankingnews.com - May 11 at 11:13 AM |
| Edited Transcript of EGRX earnings conference call or presentation 10-May-18 12:30pm GMT
finance.yahoo.com - May 11 at 9:42 AM |
| Eagle Pharmaceuticals (EGRX) Releases Earnings Results, Misses Estimates By $0.16 EPS
www.americanbankingnews.com - May 10 at 5:47 PM |
| Eagle Pharmaceuticals' (EGRX) CEO Scott Tarriff on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 10 at 5:05 PM |
| Eagle Pharmaceuticals' (EGRX) Sell Rating Reaffirmed at Mizuho
www.americanbankingnews.com - May 10 at 3:07 PM |
| Eagle Pharmaceuticals misses by $0.14, misses on revenue
seekingalpha.com - May 10 at 9:10 AM |
| Eagle Pharmaceuticals: 1Q Earnings Snapshot
finance.yahoo.com - May 10 at 9:10 AM |
| Eagle Pharmaceuticals (EGRX) Upgraded to "Buy" by BidaskClub
www.americanbankingnews.com - May 9 at 6:39 PM |
| Eagle (EGRX) Denied Unique Ryanodex J-Code - Mizuho
www.streetinsider.com - May 7 at 4:59 PM |
| Eagle Pharmaceuticals (EGRX) Downgraded by ValuEngine to "Sell"
www.americanbankingnews.com - May 3 at 11:33 PM |
| Eagle Pharmaceuticals, Inc. to Discuss First Quarter 2018 Financial Results on May 10, 2018
finance.yahoo.com - May 1 at 4:43 PM |
| $46.35 Million in Sales Expected for Eagle Pharmaceuticals (EGRX) This Quarter
www.americanbankingnews.com - May 1 at 3:35 AM |
| Eagle Pharmaceuticals, Inc. to Present at 43rd Annual Deutsche Bank Health Care Conference
finance.yahoo.com - April 30 at 4:44 PM |
| $0.60 Earnings Per Share Expected for Eagle Pharmaceuticals (EGRX) This Quarter
www.americanbankingnews.com - April 29 at 11:12 AM |
| Eagle Pharmaceuticals (EGRX) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - April 26 at 9:38 AM |
| BidaskClub Downgrades Eagle Pharmaceuticals (EGRX) to Sell
www.americanbankingnews.com - April 18 at 12:16 PM |
| William Blair Analysts Reduce Earnings Estimates for Eagle Pharmaceuticals (EGRX)
www.americanbankingnews.com - April 18 at 7:58 AM |
| Eagle Pharmaceuticals (EGRX) to Post Q2 2018 Earnings of $0.77 Per Share, William Blair Forecasts
www.americanbankingnews.com - April 17 at 6:45 AM |
| Eagle Pharmaceuticals’ Vasopressin ANDA Accepted for Filing by the FDA
finance.yahoo.com - April 16 at 8:56 AM |
| Mizuho Trims Eagle Pharmaceuticals (EGRX) Target Price to $40.00
www.americanbankingnews.com - April 15 at 5:39 PM |
| Eagle Pharmaceuticals (EGRX) Price Target Cut to $81.00
www.americanbankingnews.com - April 15 at 5:06 PM |
| Eagle Pharmaceuticals (EGRX) Cut to Strong Sell at BidaskClub
www.americanbankingnews.com - April 14 at 11:26 PM |
| Brokerages Expect Eagle Pharmaceuticals (EGRX) Will Post Quarterly Sales of $49.18 Million
www.americanbankingnews.com - April 14 at 3:51 AM |
| Eagle Pharmaceuticals (EGRX) Downgraded by ValuEngine to "Buy"
www.americanbankingnews.com - April 13 at 1:35 PM |
| Brokerages Expect Eagle Pharmaceuticals (EGRX) to Announce $0.84 Earnings Per Share
www.americanbankingnews.com - April 12 at 11:19 AM |
| Eagle Pharmaceuticals (EGRX) Upgraded at ValuEngine
www.americanbankingnews.com - April 8 at 12:54 PM |
| Head to Head Survey: Mersana Therapeutics (MRSN) versus Eagle Pharmaceuticals (EGRX)
www.americanbankingnews.com - April 4 at 5:22 PM |
| Eagle Pharmaceuticals Inc (EGRX) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - April 1 at 11:38 AM |
| Eagle Pharmaceuticals (EGRX) Given "Outperform" Rating at Royal Bank of Canada
www.americanbankingnews.com - March 31 at 6:34 PM |
| Eagle Pharmaceuticals (EGRX) Lowered to Hold at ValuEngine
www.americanbankingnews.com - March 31 at 2:40 PM |
| Eagle Pharmaceuticals (EGRX) Secures New Patent for Eagle Biologics
www.streetinsider.com - March 28 at 4:46 PM |
| Eagle Pharmaceuticals (EGRX) Lowered to "Hold" at BidaskClub
www.americanbankingnews.com - March 27 at 3:28 PM |
| Eagle Pharmaceuticals Announces New Patent for Eagle Biologics
finance.yahoo.com - March 27 at 9:23 AM |
| Eagle Pharmaceuticals (EGRX) Given Buy Rating at Piper Jaffray
www.americanbankingnews.com - March 26 at 1:26 PM |
| ValuEngine Lowers Eagle Pharmaceuticals (EGRX) to Hold
www.americanbankingnews.com - March 25 at 6:26 PM |
| BidaskClub Downgrades Eagle Pharmaceuticals (EGRX) to Hold
www.americanbankingnews.com - March 24 at 4:30 PM |
| Head to Head Survey: Eagle Pharmaceuticals (EGRX) vs. Tactile Systems Technology (TCMD)
www.americanbankingnews.com - March 21 at 11:10 PM |
| Eagle Pharmaceuticals (EGRX) Rating Reiterated by Mizuho
www.americanbankingnews.com - March 21 at 7:48 PM |
Eagle Pharmaceuticals (NASDAQ:EGRX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Eagle Pharmaceuticals (NASDAQ:EGRX) Income Statement, Balance Sheet and Cash Flow Statement
Eagle Pharmaceuticals (NASDAQ EGRX) Stock Chart for Wednesday, May, 23, 2018
Loading chart…
